TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Baclofen Effects on Smoking Urge and Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke at least 10 cigarettes per day for at least 6 months and considering quitting smoking in the next 6 months-~Exclusion Criteria:~* Planning to attempt smoking cessation within the next 4 months~* Weight less than 110 lbs. or above 220 lbs.~* Use of tobacco products other than cigarettes in the previous month.~* History of: Kidney disease, uncontrolled conditions (e.g., cardiac disease, pulmonary disease, diabetes, hypertension) Neurological disease (including stroke, mini-stroke, brain injury, Alzheimers Disease, encephalitis, meningitis, seizure disorder),Phenylketonuria Schizophrenia, Schizoaffective Disorder, Paranoid Disorder, or Schizotypal Disorder.~* Current alcohol and/or drug use disorder as indicated by a screening questionnaire, past treatment for alcohol or substance use problems unless in remission(clean and sober for past year or more) or intention to seek treatment in the next 6 months for alcohol or substance use problems.~* For women: Pregnancy, nursing, not using a reliable form of birth control.~* Allergy to baclofen, Lioresal, or Kemstro.~* Taking the following medications: antidepressants(excluding selective serotonin reuptake inhibitors), bupropion, phenothiazines, antihistamines, sedative/hypnotics, benzodiazepines, alpha blockers, beta blockers.~* Lives with someone enrolled in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Baclofen condition (Type: EXPERIMENTAL): Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
- Placebo condition (Type: PLACEBO_COMPARATOR): Placebo capsules identical to active medication, 3/day for 12 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prehab Prior to Undergoing Tricuspid Intervention

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years of age~2. Moderate-Severe or Severe TR~3. Undergoing tricuspid valve surgical or catheter-based intervention~Exclusion Criteria:~1. Clinical instability according to the judgement of the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prehabilitation (Type: None): All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Independant Task Neural Correlates of Different Levels of Mental Workload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Medical examination made before search involvement~* Between 20 and 40 years~* Right-handed~* Minimum study level : Baccalauréat~* Membership of the French social security~* Normal vision and hearing (or corrected to normal)~Exclusion Criteria:~* Sujects included in a clinical or therapeutic trial in progress~* Vision or hearing essential disorder~* Neurological or neuropsychiatric pathology current or gone~* Drug treatment which could alter brain activity (antidepressants, benzodiazepine, lithium etc)~* Pregnant, parturient or breast feeding women~* All other category of protected people

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Healthy volunteers (Type: OTHER): Adults healthy volunteers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Utility of Motorized Spiral Enteroscopy for Suspected Small Bowel Pathology

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patients with suspected small bowel pathology based on clinical presentation, small bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic enteroscopy~* Written informed consent available~Exclusion Criteria:~* Contraindications for endoscopy due to comorbidities~* Unable to provide written informed consent~* Patients with known severe GI tract inflammation, intestinal obstruction, gastroesophageal varices that preclude a safe enteroscopy procedure~* Coagulopathy or thrombocytopenia that cannot be corrected by blood product transfusion~* Pregnant patients~* Moribund patients from terminal illnesses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Study group (Type: None): Study group includes consecutive patients with suspected small bowel pathology based on clinical presentation, small bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic enteroscopy. Patients fulfilling the inclusion criteria and without exclusion criteria would undergo MSE per study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Parkinson's disease (ie, takes Levodopa (L-DOPA))~* Hoehn and Yahr stage score of 2 to 4~* Subject has sleep-maintenance insomnia~Exclusion Criteria:~* Significant skin disease that would make transdermal drug use inappropriate~* Subject received therapy with controlled-release Levodopa (L-DOPA), entacapone or Stalevo® within 28 days prior to the Baseline Visit or has received therapy with Tolcapone~* Atypical Parkinsonian syndromes~* Previous diagnosis of Narcolepsy, Sleep Apnoea Syndrome, significant Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD), moderate to severe Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Transdermal Patches
- Rotigotine (Type: EXPERIMENTAL): Rotigotine Transdermal Patches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Histologically confirmed glioblastoma multiforme or gliosarcoma~* Recurrent disease with an:~  * interval of at least 3 months following initial radiotherapy and temozolomide~ * interval of at least 3 weeks between end of surgery for recurrent disease and start of protocol therapy for patients who have undergone surgery for recurrent disease~* KPS 60% or higher~* Adequate bone marrow function Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 14 days prior to study initiation.~* Women of childbearing potential must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment.~* Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment.~Exclusion Criteria~* Histology other than astrocytoma grade IV (GBM or gliosarcoma)~* Tumor foci below the tentorium or or beyond the cranial vault~* Glioblastoma or gliosarcoma disease with leptomeningeal spread~* Patients with a history of any other cancer, unless in complete remission, and off all therapy for that disease for a minimum of 5 years~* Elevated serum aspartate aminotransferase, alanine aminotransferase, or bilirubin (unless there is medical justification for bilirubin elevation, and aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase are normal)~* Moderate to severe hepatic impairment~* Confirmed systolic blood pressure \< 100 mmHg or diastolic blood pressure \< 50 mmHg~* History of orthostatic hypotension~* Renal insufficiency or serum creatinine above the normal reference range~* Prior chemotherapy for recurrent glioblastoma with nitrosourea compounds or bevacizumab~* Prior focal radiotherapy~* Severe, active co-morbidity (e.g. cardiac disease; respiratory disease; chronic hepatitis; hematological and bone marrow diseases; severe malabsorption)~* No other active cancer~* No concurrent cytochrome P450 3A4 inducers~* No concurrent strong cytochrome P450 3A4 inhibitors~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan in combination with dose-dense temozolomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Nasopharyngeal RT-PCR positive SARS-CoV-2 patient~2. Age 20-50 years~3. BMI 18-28 kg/m2~4. Informed consent~Exclusion Criteria:~1. Symptoms: Cough, fever, shortness of breath~2. O2 saturation by pulse-oximeter below 94%~3. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes~4. Arrhythmias and/or history of arrythmia~5. Psoriasis and/or history of psoriasis~6. Neuropathy or myopathy and/or history of these~7. Hypoglycemia and/or history of hypoglycemia~8. Pre-existing hepatic disease~9. Pre-existing renal disease~10. Use of antacids within 1 week~11. Use of antibiotics within 1 week~12. Pregnancy~13. RT-PCR performed \>3 days prior to enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
- Arm 2 (Type: EXPERIMENTAL): Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
- Arm 3 (Type: ACTIVE_COMPARATOR): Chloroquine 500 mg BID for 5 days plus standard of care
- Arm 4 (Type: PLACEBO_COMPARATOR): Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically proven germ cell tumor Seminoma or nondysgerminoma origin Gonadal (testicular or ovarian) OR Extragonadal OR Retroperitoneal OR Primitive mediastinal AFP elevated and/or HCG greater than 200 mIU/mL No growing teratoma Refractory disease to any treatment line Refractory disease is defined by the elevation of AFP and/or HCG during the chemotherapy Refractory to treatment line consisting of one conventional dose of cisplatin (dose intensity greater than 33 mg/m2/week) OR at least 1 month since last course of chemotherapy with or without increase in the size of measurable lesions OR Received 2 regimens of conventional chemotherapy, typically the following: Bleomycin, etoposide, and cisplatin: 3-4 courses\* OR Etoposide and cisplatin: 4 courses\* AND Vinblastine, etoposide, ifosfamide, cisplatin: 4 courses of 3 week regimen (as standard salvage chemotherapy)\* \* Unless patients could be treated with a first line conventional treatment OR a first salvage conventional treatment especially patients who could be treated with T93 good prognosis protocol or T93 bad prognosis protocol or IT94 protocol Bidimensionally measurable disease OR Significant elevation of tumor markers: HCG, free beta-HCG, AFP OR Evaluable disease plus increase in tumor markers No germ cell CNS tumors or clinically significant CNS metastases~PATIENT CHARACTERISTICS: Age: Over 15 Performance status: ECOG 0-2 Life expectancy: Greater than 3 months Hematopoietic: WBC greater than 3,000/mm3 AND Platelet count greater than 150,000/mm3 Hepatic: Bilirubin less than 1.5 times normal SGOT/SGPT less than 2 times upper limit of normal (ULN) Alkaline phosphatase less than 2 times ULN Gamma glutamyl transferase less than 2 times ULN Renal: Creatinine less than 1.4 mg/dL Creatine clearance greater than 60 mL/min Cardiovascular: No cardiac insufficiency LVEF at least 50% Other: HIV negative No other malignancy except basal cell skin cancer~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No prior intensive chemotherapy with stem cell support Endocrine therapy: Not specified Radiotherapy: Prior prophylactic anterior irradiation of the diaphragm for stage I seminoma allowed Surgery: Not specified

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key inclusion criteria:~* Male and female patients aged 18 to 55 years.~* Diagnosis of MS as defined by the 2010 revised McDonald criteria (Polman et al 2011).~* A relapsing-remitting course of disease with:~  * at least 1 documented relapse during the previous 12 months (but not within 30 days prior to randomization ), or~ * a positive Gd-enhancing lesion on brain MRI scan at screening.~* An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at screening.~* No evidence of a relapse within 30 days prior to randomization.~Key exclusion criteria:~* A manifestation of another type of MS other than RRMS.~* Findings on screening or baseline brain MRI inconsistent with the diagnosis of MS.~* History of chronic disease of the immune system other than MS, or a known immunodeficiency syndrome.~* Score yes on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or yes on any item of the Suicidal Behavior section, except for the Non-Suicidal Self-Injurious Behavior (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.~* Women of child-bearing potential and Pregnant or nursing (lactating) women.~* Screening CBC (complete blood count) laboratory values as follows:~* Hemoglobin levels below 10.0 g/dL~* Total leukocyte count less than 3,000 cells/µL~* Neutropenia, defined as absolute neutrophil counts less than 1500 cells/mm3~* Platelets less than 100,000/µL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- VAY736 (Type: EXPERIMENTAL): Intravenous infusion of VAY736
- Placebo to VAY736 (Type: PLACEBO_COMPARATOR): Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent.~* Age ≥ 18 years and of either sex.~* Willing to comply with protocol instructions, including allowing all study assessments.~* Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 2.0 cm2 and ≤ 12.0 cm2~* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.~* Arterial supply adequacy confirmed~* Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone.~* Target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months).~* Acceptable state of health and nutrition~Exclusion Criteria:~* History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B.~* Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication.~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study.~* A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).~* Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.~* Refusal of or inability to tolerate compression therapy.~* Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit.~* History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).~* Any prior exposure to HP802-247 or its vehicle.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HP802-247 plus compression therapy (Type: EXPERIMENTAL): HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
- HP802-247 Vehicle plus compression therapy (Type: PLACEBO_COMPARATOR): fibrinogen solution \& thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Untreated AML except patients with inv (16), t(8;21), or t (15;17) cytogenetics or AML in first relapse.~2. Patients must have \>/= 2,000 circulating blasts/ul peripheral blood or \>/= 50% blasts in bone marrow biopsy~3. Performance Status 0-2~Exclusion Criteria:~1. Medical, social or psychological factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure.~2. Concurrent or expected need for therapy with corticosteroids during the vaccination phase of the study.~3. History of systemic autoimmune disease~4. Positive antibody to human immunodeficiency virus~5. Patients with Acute promyelocytic Leukemia are not eligible for this study.~6. Good-risk cytogenetics which are: (inv (16), t(8;21), or t (15;17)~7. Positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous Dendritic Cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues